Trial Profile
Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb7195
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Jan 2018
Price :
$35
*
At a glance
- Drugs AIMab 7195 (Primary) ; AIMab 7195 (Primary)
- Indications Allergic asthma; Hypersensitivity
- Focus Pharmacokinetics
- Sponsors Xencor
- 05 Jan 2018 According to a Xencor media release, data from the subcutaneous Phase 1b study were announced in November 2017.
- 09 May 2017 According to a Xencor media release, top-line data is expected in 2017.
- 01 May 2017 Status changed from active, no longer recruiting to completed.